Drug trial aims to shield patients from harsh chemo side effects while fighting bladder cancer
NCT ID NCT04887831
Summary
This study tested if adding a drug called trilaciclib to standard first-line chemotherapy and immunotherapy could better control advanced bladder cancer. The goal was to see if trilaciclib could help patients live longer without their cancer worsening while also protecting their bone marrow from chemotherapy's damaging side effects. The trial enrolled 92 adults with untreated, advanced bladder cancer and was terminated early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ALTHAIA, Xarxa Assistencial Universitiria de Manresa
Manresa, Barcelona, 08243, Spain
-
Beacon Cancer Center PLLC
Coeur d'Alene, Idaho, 83814, United States
-
Centre Léon Bérard - Département d'oncologie médicale
Lyon, 69373, France
-
Florida Cancer Specialists - North
St. Petersburg, Florida, 33705, United States
-
Florida Cancer Specialists - South
Fort Myers, Florida, 33901, United States
-
Fundación Instituto Valenciano de Oncología
Valencia, 46009, Spain
-
H.U. V. de las Nieves
Granada, 18014, Spain
-
High Technology Hospital MedCenter LTD
Batumi, Adjara, 6010, Georgia
-
Hopitaux Universitaires de Strasbourg - Service Oncologie et Hématologie
Strasbourg, Bas-Rhin, 67091, France
-
Hospital Clinic de Barcelona - Servicio de Oncología Médica
Barcelona, 08036, Spain
-
Hospital Politecnic Universitari La Fe
Valencia, 46026, Spain
-
Hospital Universitario Lucus Augusti
Lugo, 27003, Spain
-
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, Madrid, 28222, Spain
-
Hospital Universitario Vall d´Hebron
Barcelona, 08035, Spain
-
Hospital de la Santa Creu i Sant Pau
Barcelona, 08041, Spain
-
Hôpital Européen Georges Pompidou - Service d'Oncologie Médicale
Paris, 75015, France
-
Institut Bergonié - Oncologie Médicale et Pédiatrique
Bordeaux, Gironde, 33076, France
-
Institut Català d'Oncologia-Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, 08916, Spain
-
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, 54519, France
-
Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz - Rendeloint
Szolnok, Jász-Nagykun-Szolnok, H-5000, Hungary
-
LTD "Multiprofile Clinic Consilium Medulla"
Tbilisi, 186, Georgia
-
Montefiore Medical Center
The Bronx, New York, 10461, United States
-
National Center of Urology Named after Laur Managadze
Tbilisi, 0144, Georgia
-
New York Oncology Hematology, P.C.
Albany, New York, 12206, United States
-
Northwest Cancer Specialists, P.C.
Tigard, Oregon, 46241, United States
-
Országos Onkológiai Intézet
Budapest, 1122, Hungary
-
Rocky Mountain Cancer Centers
Littleton, Colorado, 80120, United States
-
Tennessee Oncology, PLLC
Nashville, Tennessee, 37203, United States
-
The Harry and Jeanette Weinberg Cancer Institute
Baltimore, Maryland, 21237, United States
-
The Oncology Institute of Hope and Innovation
Whittier, California, 90603, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
-
Uzsoki Utcai Kórház
Budapest, H-1145, Hungary
-
Valkyrie Clinical Trial
Los Angeles, California, 90067, United States
-
Woodlands Medical Specialists
Pensacola, Florida, 32503, United States
Conditions
Explore the condition pages connected to this study.